-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the State Medical Products Administration approved the registration
of the innovative product "aspheric diffraction multifocal intraocular lens" produced by Ibonold (Beijing) Medical Technology Co.
, Ltd.
after review.
of the innovative product "aspheric diffraction multifocal intraocular lens" produced by Ibonold (Beijing) Medical Technology Co.
, Ltd.
after review.
The aspheric diffraction multifocal intraocular lens is a one-piece/posterior chamber intraocular lens that is foldable and has a modified L-shaped
loop.
The main body and support parts of the product are made of ethyl acrylate and ethyl methacrylate copolymer materials, with the addition of ultraviolet absorbers, and the surface is modified by heparin
.
The innovation of the product is that its optical part adopts a combination of diffraction spectroscopy and aspheric design, and diffraction technology is the core of realizing multi-focus, which is the first in China
.
loop.
The main body and support parts of the product are made of ethyl acrylate and ethyl methacrylate copolymer materials, with the addition of ultraviolet absorbers, and the surface is modified by heparin
.
The innovation of the product is that its optical part adopts a combination of diffraction spectroscopy and aspheric design, and diffraction technology is the core of realizing multi-focus, which is the first in China
.
The product is used for vision correction in adult cataract patients, and is expected to provide two foci, far and near, to a certain extent, to make up for the lack of poor vision of monofocal intraocular
lenses.
The launch of the product will bring new treatment options
to patients.
lenses.
The launch of the product will bring new treatment options
to patients.
The drug regulatory department will strengthen the post-market supervision of the product to protect the safety
of patients' devices.
of patients' devices.
